Stakeholders: Regulatory expectations during COVID-19 pandemic
Published: 29/6/2020
How COVID-19 is affecting my GMP/GDP licence when renewal is approaching
The European Medicine Agency, together with heads of the Medicine Agencies across the Continent have released a new version for their guidance on regulatory expectations for the medicinal products in the midst of the pandemic of COVID 19. This will add a new section laying out some temporary flexibilities for GMP and GDP.